OS Therapies Completes OST-HER2 Phase 2b Trial Enrollment and Final Treatment Dose

OS Therapies Incorporated (NYSE American: OSTX) announced today that the last patient (Patient #41) in the AOST-2121 clinical trial of OST-HER2 for recurrent, resected Osteosarcoma has received their final treatment dose. This patient is expected to complete the final radiological…

Read MoreOS Therapies Completes OST-HER2 Phase 2b Trial Enrollment and Final Treatment Dose

Jupiter Endovascular Gets FDA Nod for Vertex Pulmonary Embolectomy System Pivotal Study

Jupiter Endovascular, Inc., a medical tech innovator specializing in advanced endovascular procedures through Endoportal Control™, has received FDA approval for its Investigational Device Exemption application. This approval clears the way for the SPIRARE II U.S. pivotal study (NCT06576427) to advance,…

Read MoreJupiter Endovascular Gets FDA Nod for Vertex Pulmonary Embolectomy System Pivotal Study

Renata Medical’s Minima Growth Stent Gains FDA Approval for Aortic Coarctation and Pulmonary Artery Stenosis

Renata Medical has announced that the U.S. Food and Drug Administration (FDA) has approved its innovative Minima Growth Stent, designed specifically for neonates, infants, and young children. This unique stent is engineered to be re-expanded as the child grows, offering…

Read MoreRenata Medical’s Minima Growth Stent Gains FDA Approval for Aortic Coarctation and Pulmonary Artery Stenosis

Alnylam Shares HELIOS-B Phase 3 Results on Vutrisiran for ATTR Amyloidosis at ESC Congress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented at…

Read MoreAlnylam Shares HELIOS-B Phase 3 Results on Vutrisiran for ATTR Amyloidosis at ESC Congress